Endocrine Abstracts

Empagliflozin is a potent, highly selective sodium glucose cotransporter-2 inhibitor in development for treatment of type 2 diabetes mellitus. This randomized, placebo-controlled, double-blind study assessed the effects of empagliflozin on the QT interval. Thirty healthy subjects (14/16 female/male; mean [range] age 34.5 [18–52] years) received single doses of 25 mg (within therapeutic range) and 200 mg (supratherapeutic) empagliflozin and 400 mg moxifloxacin as positive ...